Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPONT's CURRENT AMPLIGEN PRODUCTION WILL SUPPLY UP TO 5,000 PATIENTS

Executive Summary

DuPONT's CURRENT AMPLIGEN PRODUCTION WILL SUPPLY UP TO 5,000 PATIENTS in expanded clinical trials, DuPont Pharmaceuticals and Biotechnology R&D Director Joseph Mollica told the Presidential AIDS Commission's Feb. 19 meeting in New York City. In an update on the status of the antiviral agent jointly being developed by DuPont and HEM Research, Mollica told the commission that production of Ampligen "is being increased to a maximum capacity to support about 5,000 patients, enough for trials, but not enough for commercialization." DuPont is planning to scale up its own production capability for further trials and "possible commercialization" in approximately two-and-a-half years. In the meantime, the firm has approached other manufacturers to contract out individual segments of the production, Mollica said. Ampligen is currently being produced in lab scale quantities of less than 10 kg per year, enough for only a few hundred patients, according to Mollica. Since DuPont signed its agreement with HEM in October, a multicenter, double-blind, randomized trial in male patients with ARC has been accelerated. The study is underway at centers in New York, Philadelphia, Washington, D.C., Atlanta, Houston, and Miami. The trial is expected to be completed in one year, Mollica said.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel